oncoExTra®
by EXACT SCIENCES

Covered by MEDICARE

# A Comprehensive and Easy to Interpret Clinical Report

The OncoExTra® assay is an **ultra-comprehensive genomic profiling test** that incorporates whole-exome and whole-transcriptome* sequencing to identify alterations/biomarkers in patients diagnosed with all types of advanced cancers. These insights can help inform targeted therapy or immunotherapy selection, and clinical trials eligibility.

## The OncoExTra Test Provides:

- 3 report types: OncoExTra + IHC†, OncoExTra Only, or IHC Only
- Easy to interpret "Results Snapshot" on page 1 of the report
- Color coded sections to help correlate findings

**Drugs predicted to have no or reduced benefit as supported by literature**

**Additional therapeutic options outside of patient's cancer sub-type**

**Targetable Mutations and Associated Therapies**

**TMB & MSI Status**

**High Interest Biomarkers**



oncoExTra®

EXACT SCIENCES

Report Date: MM/DD/YYYY

| | | | |
|---|---|---|---|
| Patient: | Sample Patient | Ordering Client: | Medical Center |
| Sex at Birth: | Female | Specimen Type: | FFPE Block |
| DOB: | MM/DD/YYYY | Specimen Site: | Lung |
| Medical Record #: | MR [illegible] | Tumor Collection Date: | MM/DD/YYYY |
| Client Accession #: | CA 000000 | Normal Collection Date: | MM/DD/YYYY |
| Ordering Physician: | Sample Physician | Received Date: | MM/DD/YYYY |

**Results Snapshot**
Analytes sequenced: DNA+RNA+IHC
Actionable Targets: 5 | IHC Tested: 1
TMB: Intermediate | PD-L1: See Below
MSI: Stable
Clinical Trials: Yes

Diagnosis: **Lung Cancer**

KEY BIOMARKER FINDINGS

| KEY BIOMARKERS | FDA-APPROVED DRUGS -for patient's cancer† | FDA-APPROVED DRUGS -for another cancer† | DRUGS PREDICTED NON-BENEFICIAL/ REDUCED BENEFIT | POTENTIAL CLINICAL TRIALS |
|---|---|---|---|---|
| TUMOR GENOMIC ALTERATIONS | | | | |
| ARID1A (S2249*) | | | | Yes |
| CD74/ROS1 | crizotinib, entrectinib | cabozantinib, ceritinib, lorlatinib | | Yes |
| NF1 (Q369*) | | binimetinib, everolimus, temsirolimus, trametinib | | Yes |
| TP53 (I195T) | | | | Yes |
| TUMOR MUTATION BURDEN (TMB) | | | | |
| INTERMEDIATE (8 mut/Mb) | | | | No |
| MICROSATELLITE STATUS (MSI) | | | | |
| STABLE | | | | No |
| IHC RESULTS | | | | |
| PD-L1 (22C3): Low | atezolizumab, durvalumab, nivolumab, nivolumab + ipilimumab, pembrolizumab | dostarlimab-gxly | | |

HIGH INTEREST BIOMARKERS

*As part of the OncoExTra test, key biomarkers relevant in the patient's tumor type have been assessed: **NTRK1, NTRK2, NTRK3, RET, BRAF, ALK, EGFR, ERBB2, KRAS, MET, ROS1, PD-L1**. If clinically pertinent event(s) in these biomarkers have been identified, the biomarker(s) will appear within the 'Key Biomarker Findings' section of the report. If Biomarkers from this list do not appear, clinically pertinent event(s) have not been identified or fell outside of the OncoExTra reporting thresholds (please see Disclaimer Limitations information).*

†The prescribing information for the FDA-approved therapeutic option may not include the associated Key Biomarker.

Janine LoBello, DO, Laboratory Director
Genomic Health, Inc. 445 N 5th Street Phoenix, AZ 85004 tel:1-866-662-6897

Page 1 of 19



**Snapshot of Key findings**

**Clinical Trial Options**

**IHC Results with therapeutic indications**

*Whole-transcriptome with select variants reported in New York State
†IHC testing is not currently available in New York State

# Additional Report Details

## Additional Significant Alterations

| ADDITIONAL SIGNIFICANT ALTERATIONS | |
|---|---|
| MAP2K4 (R228I) | No |

## Genomic Alteration Detail

| Genomic Alteration | | Therapeutic Implication | |
|---|---|---|---|
| Alteration: | ARID1A (S2249*) | **Drug** | **Status** |
| Alteration Type: | Stop Gain | See Clinical Trials Section | |
| Coordinate: | chr1:27107135 | | |
| Allele Frequency: | 24% | | |
| Origin: | DNA | | |
| Read Depth: | 465 | | |
| Location: | 20/20 | | |

## Drug Evidence Detail

Literature Supporting Therapeutic Implication

| Drug | Biomarker | Therapeutic Implication |
|---|---|---|
| **ceritinib (Zykadia)** | CD74/ROS1 (Fusion) | PREDICTED BENEFICIAL |

*ROS1 rearranged NSCLC patients (n=32) were enrolled in a phase II ceritinib trial. The ORR was 63% with 1 complete response and 19 partial responses. The median duration of response was 10.0 months. The median PFS was 19.3 months and the median OS was not reached at the time of the data cut off.*

## Clinical Trials

**Potential trials based on genomic targets indicated in the OncoExTra Report**

| Genomic Alterations | Targeted Investigational Agents | Trial IDs |
|---|---|---|
| ARID1A (S2249*) | AKT inhibitors: (Afuresertib [GSK2110183], Capivasertib [AZD-5363], Ipatasertib [GDC-0068, RG-7440], Miransertib [ARQ092], ARQ751, MK-2206, Triciribine [TCN-P]), ATR inhibitors: (Berzosertib [M | NCT05023655 NCT02264678 NCT02484404 NCT05053971 NCT01582191 NCT03065062 |

## IHC Score Detail

1 IHC Tested

| IHC BIOMARKER | IHC Data | Status | Approved By |
|---|---|---|---|
| PD-L1 (22C3) | %TPS: 5-9 | Low | Dr. Sample Pathologist (MM/DD/YEAR) |

**To Learn More: OncoExTra.com | To Order: OncoExTra.com/order**

EXACT SCIENCES

OncoExTra has been validated according to the guidelines set forth by the New York State Department of Health. Whole exome (DNA) events have been validated to include point mutations, indels, and copy number alterations, as well as MSI analysis and TMB calculation. Whole transcriptome (RNA) has been validated to report on select fusion genes and special transcripts.